Liraglutide - Weight management in adults

You are here : Home > Formulary Search > Liraglutide - Weight management in adults

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red

Formulations :

Subcutaneous injection (sc)

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

BNF SPC

Restrictions / Comments :

Documentation

Guidelines (Local)

Saxenda referral criteria and pathway - Oct 2021

NICE Technology Appraisal

NICE TA664 - Liraglutide for managing overweight and obesity

PAD Profile

ChemicalSubstance :

Liraglutide

Indication :

Weight management in adults

Group Name :

Keywords :

obesity, overweight, weight loss

Brand Names Include :

Saxenda, Nevolat, Biolide

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Supporting Documents :

Other Indications

Below are listed other indications that Liraglutide is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Weight management in adults.

Committee Recommendations (2)

05 Jul 23 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

A Medicines Shortage Notification has been issued in relation to the supply shortages of GLP-1s.

See GLP-1 Medicine Shortage document below for full details

03 Mar 21 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The APC recommends the use of liraglutide (prescribed as Saxenda) as an option for managing overweight and obese patients in line with NICE TA664 (see link to NICE below).

Liraglutide (Saxenda) will be considered RED on the traffic light system.

Weight management local guidance will be updated and referreal criteria to be developed with ASPH